Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations

Cited by (179)

Items 101–179 of 179

1. A Neuro-oncologist’s Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer
   Tresa Michelle McGranahan, Seema Nagpal · 2017 · Current Treatment Options in Oncology
2. Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection
   Hyungjin Kim, Kum Ju Chae, Soon Ho Yoon, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong‐Wan Kim, Jin Mo Goo, Chang Min Park · 2017 · European Radiology
3. Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
   Yuki Takeyasu, Tatsuya Yoshida, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe · 2024 · JTO Clinical and Research Reports
4. Comparison of T790M Acquisition After Treatment With First- and Second-Generation Tyrosine-Kinase Inhibitors: A Systematic Review and Network Meta-Analysis
   Po‐Chun Hsieh, Yao‐Kuang Wu, Chun-Yao Huang, Mei-Chen Yang, Chan‐Yen Kuo, I‐Shiang Tzeng, Chou‐Chin Lan · 2022 · Frontiers in Oncology
5. Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF
   Stephanie Kim Cheok, Azeet Narayan, Anna Arnal Estape, Scott N. Gettinger, Sarah B. Goldberg, Harriet M. Kluger, Don X. Nguyen, Abhijit A. Patel, Veronica Chiang · 2021 · JCO Precision Oncology
6. A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor
   Jing Zhao, HUA-HUA FENG, Jinyin Zhao, LI-CHENG LIU, Feifei Xie, Yan Xu, MIN-JIANG CHEN, Wei Zhong, Longyun LI, HAN-PING WANG et al. · 2016 · Oncology Letters
7. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI
   Chi‐Lu Chiang, Hsu-Ching Huang, Chia‐I Shen, Yung‐Hung Luo, Yuh‐Min Chen, Chao‐Hua Chiu · 2020 · Targeted Oncology
8. T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer
   Jacky Yu-Chung Li, Jcm Ho, Kam-Hung Wong · 2018 · Oncotarget
9. Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas ® EGFR mutation test
   Miyako Satouchi, Hiroshi Tanaka, Hiroshige Yoshioka, Tadasuke Shimokawaji, Keiko Mizuno, Koji Takeda, Ichiro Yoshino, Takashi Seto, Takayasu Kurata, Naoki Tashiro et al. · 2017 · Lung Cancer
10. Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis
    Yo Kawaguchi, Jun Hanaoka, Hideki Hayashi, Naoki Mizusaki, Hirotoshi Iihara, Yoshinori Itoh, Tadashi Sugiyama · 2016 · Chemotherapy
11. Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
    Sung Won Lim, Sehhoon Park, Youjin Kim, Jang Ho Cho, Song Ee Park, Hansang Lee, Hee Kyung Kim, Sung Min Kim, Jong Mu Sun, Se‐Hoon Lee et al. · 2018 · Lung Cancer
12. A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
    Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon‐Gu Kim et al. · 2018 · Cancer Research and Treatment
13. Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC
    Shuai Li, Fangyu Zhou, Shengxiang Ren, Caicun Zhou · 2014 · Lung Cancer
14. Precision cytopathology: expanding opportunities for biomarker testing in cytopathology
    Adriana Morales Sánchez, Therese J. Bocklage · 2018 · Journal of the American Society of Cytopathology
15. Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy
    Won Gun Kwack, Ji‐Youn Sung, Seung Hyeun Lee · 2021 · Frontiers in Oncology
16. Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFRCSTMLR mutant protein: molecular modeling and free energy approach
    Ravi Prakash Saini, Sonali Kumari, Aditi Bhatnagar, Amit Kant Singh, Abha Mishra · 2023 · Scientific Reports
17. Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs
    Jietao Ma, Le‐Tian Huang, Cheng‐Bo Han · 2024 · Therapeutic Advances in Medical Oncology
18. Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment
    Justine Leonie Kuiper, Daniëlle A.M. Heideman, Tom Würdinger, Katrien Grünberg, Harry J.M. Groen, Egbert Frederik Smit · 2014 · Clinical Lung Cancer
19. Effect of AXL on the epithelial-to-mesenchymal transition in non-small cell lung cancer
    Xueming Ying, Jun Chen, Xueming Huang, Peng Huang, Shao-Cong Yan · 2017 · Experimental and Therapeutic Medicine
20. Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs
    Taira Ninomaru, Akito Hata, Chiyuki Kokan, Hideaki Okada, Hirotaka Tomimatsu, Jun Ishida · 2021 · Thoracic Cancer
21. Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital
    Venkata Pradeep Babu Koyyala, Ullas Batra, Parveen Jain, Mansi Sharma, Pankaj Goyal, Pavani Medisetty, Ankush Jajodia, Udip Maheshwari · 2018 · Lung India
22. Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
    Corey Allan Carter, Bryan T. Oronsky, Scott Z. Caroen, Jan J. Scicinski, Pedro Cabrales, Aiste Degesys, Christina E. Brzezniak · 2016 · Respiratory Medicine Case Reports
23. A case of resistance to tyrosine kinase inhibitor therapy
    Yanjun Xu, Zhiyu Huang, Lei Gong, Yun Fan · 2017 · Anti-Cancer Drugs
24. Successful Treatment with Osimertinib and Chemotherapy in a Non–Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis
    Hironori Yoshida, Masahiro Ooi, Young Hak Kim · 2018 · Journal of Thoracic Oncology
25. Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding
    Antonio Passaro, Letizia Gianoncelli, Valeria Stati, Filippo de Marinis · 2019 · Annals of Translational Medicine
26. Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report
    Takehiro Uemura, Tetsuya Oguri, Minami Okayama, Hiromi Furuta, Yoshihiro Kanemitsu, Osamu Takakuwa, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito et al. · 2017 · Molecular and Clinical Oncology
27. Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis
    Evangelos Tsiambas, NICHOLAS S. MASTRONIKOLIS, Alicia Yioli Lefas, Stavros N Georgiannos, Vasileios Ragos, Panagiotis P Fotiades, Nikolaos Tsoukalas, Nikolaos Kavantzas, Andreas Karameris, Dimitrios Peschos et al. · 2017 · In Vivo
28. T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas HarboringEGFRMutations
    Yoshihito Kogure, Fumie Shigematsu, Masahide Oki, Hideo Saka · 2018 · In Vivo
29. CT Radiomics Predict EGFR-T790M Resistance Mutation in Advanced Non-Small Cell Lung Cancer Patients After Progression on First-line EGFR-TKI
    Xin Tang, Yuan Li, Li-Ting Shen, Wei‐Feng Yan, Wen-Lei Qian, Zhi‐gang Yang · 2023 · Academic Radiology
30. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
    Yosuke Togashi, Hidetoshi Hayashi, Kazuhiko Nakagawa, Kazuto Nishio · 2014 · Drug Design Development and Therapy
31. Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis
    Xiao-Fang Yi, Jun Song, Ruo-Lin Gao, Li Sun, Zhixuan Wu, Shuling Zhang, Le‐Tian Huang, Jie‐Tao Ma, Cheng‐Bo Han · 2022 · Frontiers in Oncology
32. Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib
    Riziero Esposito Abate, Raffaella Pasquale, Alessandra Sacco, Maria Carmela Piccirillo, Alessandro Morabito, Paolo Bidoli, Giovanna Finocchiaro, Rita Chiari, Luisa Foltran, Roberta Buosi et al. · 2019 · Cancers
33. Readministration of EGFR Tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients after Initial Failure, What Affects its Efficacy?
    Ze-Rui Zhao, Wěi Li, Hao Long · 2014 · Scientific Reports
34. Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options
    Jordi Remón, Benjamin Besse · 2016 · ESMO Open
35. Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
    Chee-Shee Chai, Chong Kin Liam, Mau Ern Poh, Diana Bee‐Lan Ong, Yong‐Kek Pang, Phaik‐Leng Cheah, Gwo Fuang Ho, Adlinda Alip · 2020 · Cancer Management and Research
36. Methodological comparison of the allele refractory mutation system and direct sequencing for detecting EGFR mutations in NSCLC, and the association of EGFR mutations with patient characteristics
    Minmin Wu, Xiaodong Pan, Yaya Xu, Siying Wu, Xiuling Wu, Bicheng Chen · 2018 · Oncology Letters
37. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs
    Fei Zhou, Wanrong Ma, Wěi Li, Huijuan Ni, Guanghui Gao, Xiaoxia Chen, Jie Zhang, Jingyun Shi · 2018 · BMC Cancer
38. Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation
    Amit Kant Singh, Abha Mishra · 2022 · Journal of Biomolecular Structure and Dynamics
39. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
    Takahisa Kawamura, Hirotsugu Kenmotsu, Haruki Kobayashi, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita P. Mori et al. · 2019 · Investigational New Drugs
40. Current chemotherapeutic regimens for brain metastases treatment
    Joo Yeon Nam, Barbara Jane O'Brien · 2017 · Clinical & Experimental Metastasis
41. Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis
    Ruofan Huang, Mengxi Ge, Xinli Zhou, Xiaoyu Ji, Li Liao, Xiaohua Liang, Qiong Zhan · 2018 · Cancer Biotherapy and Radiopharmaceuticals
42. Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
    Ji Yeon Kim, Woo Jeong Lee, Ha Young Park, Ahrong Kim, Dong‐Hoon Shin, Chang Hun Lee · 2018 · Journal of Pathology and Translational Medicine
43. High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
    Ji‐Youn Sung, Dong-Won Park, Seung Hyeun Lee · 2022 · Biomedicines
44. Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma
    Ryota Kanemaru, Yoshiteru Morio, Hidenori Takekawa, Hitomi Jo, Fumiko Kasuga, Ryo Koyama, Satomi Shiota, Tetsutaro Nagaoka, Kazuhisa Takahashi · 2016 · Respiratory Investigation
45. Development, validation, and comparison of gene analysis methods for detecting EGFR mutation from non-small cell lung cancer patients-derived circulating free DNA
    Masaki Hanibuchi, Akira Kanoh, Takuya Kuramoto, Tatsuro Saito, Makoto Tobiume, Atsuro Saijo, Hiroyuki Kozai, Mayo Kondo, Shun Morizumi, Hiroto Yoneda et al. · 2019 · Oncotarget
46. Novel allosteric inhibitor to target drug resistance in EGFR mutant: molecular modelling and free energy approach
    Amit Singh, Ravi Prakash Saini, Abha Mishra · 2022 · Molecular Simulation
47. Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients
    Javier Simarro, Gema Pérez-Simó, Nuria Mancheño, Emilio Ansótegui, Carlos Francisco Muñoz-Núñez, José Gómez‐Codina, Óscar Juan, Sarai Palanca · 2022 · International Journal of Molecular Sciences
48. Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors
    Justine Leonie Kuiper, Egbert Frederik Smit · 2014 · Oncology
49. Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
    Fernando López‐Ríos, Javier de Castro, Ángel Concha, Pilar Garrido, Javier Gómez‐Román, Dolores Isla, José Ramírez, Luis G Paz-Ares, Julián Sanz‐Ortega, Enriqueta Felip · 2014 · Revista Española de Patología
50. The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer
    Wen‐Chien Cheng, Yi‐Cheng Shen, Chieh‐Lung Chen, Wei-Chih Liao, Hung-Jen Chen, Te‐Chun Hsia, Chia‐Hung Chen, Chih‐Yen Tu · 2022 · Diagnostics
51. Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center
    Hazem I. Assi, Arafat Tfayli, Nada Assaf, Sarah Abou Daya, Aram Bidikian, Dima Kawsarani, Puzant Fermanian, Ghazi S Zaatari, Rami A. Mahfouz · 2019 · Molecular Biology Reports
52. Harnessing cuproptosis: a new avenue for targeted cancer therapies
    Anil Dharavath, Sivkan Kaur, PV Drupad Mohan, Santosh Kumar Guru · 2025 · APOPTOSIS
53. Acquired Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound–Guided Transbronchial Needle Aspiration Samples
    Elena Guerini‐Rocco, Antonio Passaro, Chiara Casadio, Valeria Midolo De Luca, Juliana Guarize, Filippo de Marinis, Davide Vacirca, Massimo C.P. Barberis · 2018 · Archives of Pathology & Laboratory Medicine
54. Multi-line treatment with tyrosine kinase inhibitors enabled in 4-year survival for patient with stage IV lung adenocarcinoma: a case report
    Yan Yin, Jianwen Qin · 2020 · Annals of Palliative Medicine
55. Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer and Eye Metastasis: Disease Relapse or a New Entity?
    Paul Zarogoulidis, Sofia Lampaki, Panos Chinelis, George Lazaridis, Sofia Baka, Aggeliki Rapti · 2016 · Medical Hypothesis Discovery & Innovation in Ophthalmology
56. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma
    Akimasa Sekine, Terufumi Kato, Tae Iwasawa, Tomohisa Baba, Akihiro Suido, Haruyasu Sakuranaka, Masaaki Futaki, Takashi Ogura · 2016 · Internal Medicine
57. Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report
    Ma, Chunhua, Wang, Shuyuan, Mu, Ning, Li, Jinduo, Liu, Mei, Li, Lin, Jiang, Rong · 2020 · Frontiers in Oncology
58. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era
    Alessia Spagnuolo, Matteo Muto, Fabio Monaco, Giuseppe Colantuoni, Cesare Gridelli · 2019 · Translational Lung Cancer Research
59. Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status
    Jun Liao, Yihua Huang, Jiadi Gan, Lanlan Pang, Wael Abdullah Sultan Ali, Yunpeng Yang, Likun Chen, Li Zhang, Wenfeng Fang · 2022 · Cancer Control
60. Treatments and outcomes of advanced/recurrent non-small cell lung cancer harboring theEGFRT790M mutation: a retrospective observational study of 141 patients in Japan
    Yuki Yamane, Ayako Shiono, Yoshiki Ishii, Kazutoshi Isobe, Eisaku Miyauchi, Kazuma Kishi, Makoto Nishino, Shunichi Sugawara, Ryo Ko, Nobuyuki Koyama et al. · 2016 · Japanese Journal of Clinical Oncology
61. EGFR Mutations
    Anna Manzo, Agnese Montanino, Raffaele Costanzo, Claudia Sandomenico, Giuliano Palumbo, Clorinda Schettino, Gennaro Daniele, Alessandro Morabito, Francesco Perrone, Maria Carmela Piccirillo · 2018 · Elsevier eBooks
62. T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma.
    Hanifeh Mirtavoos‐Mahyari, Azizollah Abbasi Dezfouli, Zahra Esfahani‐Monfared, Adnan Khosravi, Sharareh Seifi, Kambiz Sheikhy · 2022 · PubMed Central
63. Three Cases of an Unsuccessful Histopathological Diagnosis of Bronchoscopic Re-biopsy Specimens from EGFR-mutant Adenocarcinoma Patients After EGFR-TKI Therapy
    Kei Morikawa, Noriaki Kurimoto, Kazutaka Kakinuma, Naoki Furuya, Teruomi Miyazawa, Masamichi Mineshita · 2016 · Haigan
64. Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon
    Siba El Hussein, Samer N. Khader · 2019 · Diagnostic Cytopathology
65. Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report
    Junid A. Naveed Ahmad, Bowen He, Brett Schroeder, Joseph Rosales · 2022 · International Journal of Cancer Care and Delivery
66. Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients
    Pang-Shuo Perng, Heng-Juei Hsu, Jung‐Shun Lee, Liang‐Chao Wang, Chih‐Yuan Huang, Chih‐Hao Tien, Yu‐Hsuan Lai, Po‐Lan Su, Hao‐Hsiang Hsu, Liang-Yi Chen et al. · 2023 · World Journal of Surgical Oncology
67. Considerations on the Management of EGF Receptor-TKIs For Brain Metastases In EGFR -Mutant Lung Carcinoma Patients
    Masato Shingyoji, Toshihiko Iuchi · 2015 · Lung Cancer Management
68. The Clinical Strategy to Overcome EGFR-TKI Acquired Resistance for NSCLC Patients
    Li Li · 2016 · International Journal of Cancer and Oncology
69. Les rebiopsies : pourquoi ? Comment ?
    A. Saint-Paul, Julia Ballouhey, Alain Vergnenégre · 2017 · Revue des Maladies Respiratoires Actualités
70. Métastases cérébrales des cancers bronchiques non à petites cellules (CBNPC)
    I. Monnet · 2017 · Revue des Maladies Respiratoires Actualités
71. Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance
    LinFang Wang, SuLong Jiang · 2014
72. Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients
    Filiz Güldaval, Ceyda Mahlec Anar, Melih Büyükşirin, Merve Ayık Türk, Günseli Balcı, Mine Gayaf, Murat Akyol, İbrahim Onur Alıcı, Gülru Polat, Gülistan Karadeniz et al. · 2021 · Kocaeli Medical Journal
73. Hirnmetastasen
    Christian Klaus Jochen Schulz, Martin Andreas Proescholdt, Nils Ole Schmidt, Felix Steger, Daniel Heudobler · 2024 · Pneumologie
74. Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with unknown T790M mutation: a case report and review of literature
    Mariem Hachlaf, Sihame Lkhoyaali, Wydad Nadir, Hajar Lemsyeh, Brahim el Ghissassi, Hind M’rabti, Saber Boutayeb, Hassan H Errihani · 2024 · Journal of Medical Case Reports
75. EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report
    Maria F. Martínez-Hernandez, Luis Lara‐Mejía, Carlos Izquierdo-Tolosa, Luis Antonio Cabrera-Miranda, Oscar G. Arrieta · 2024 · Oncology Research and Treatment
76. Hirnmetastasen
    Christian Klaus Jochen Schulz, Martin Andreas Proescholdt, Nils Ole Schmidt, Felix Steger, Daniel Heudobler · 2025 · TumorDiagnostik & Therapie
77. Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR ‐Mutated Advanced Nonsmall‐Cell Lung Cancer
    Chia‐Yu Kuo, Tien‐Chi Huang, Chih‐Jen Yang, Mei–Hsuan Lee, Jui‐Ying Lee, Ying‐Ming Tsai, Kuan‐Li Wu, Cheng‐Hao Chuang, Inn‐Wen Chong, Jen‐Yu Hung · 2025 · The Kaohsiung Journal of Medical Sciences
78. Additional file 1 of Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients
    Perng, Pang-Shuo, Hsu, Heng-Juei, Lee, Jung-Shun, Wang, Liang-Chao, Huang, Chih-Yuan, Tien, Chih-Hao, Lai, Yu-Hsuan, Su, Po-Lan, Hsu, Hao-Hsiang, Chen, Liang-Yi et al. · 2024 · Figshare
79. Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR
    Simon Baldacci · 2017